Tamer Coskun
About
In The Last Decade
Tamer Coskun
5 papers receiving 775 citations
Hit Papers
Peers
Comparison fields: 5 of 65
- Endocrinology, Diabetes and Metabolism 566
- Pharmacology 356
- Physiology 292
- Molecular Biology 194
- Surgery 157
Countries citing papers authored by Tamer Coskun
This map shows the geographic impact of Tamer Coskun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamer Coskun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamer Coskun more than expected).
Fields of papers citing papers by Tamer Coskun
This network shows the impact of papers produced by Tamer Coskun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamer Coskun. The network helps show where Tamer Coskun may publish in the future.
Co-authorship network of co-authors of Tamer Coskun
This figure shows the co-authorship network connecting the top 25 collaborators of Tamer Coskun. A scholar is included among the top collaborators of Tamer Coskun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamer Coskun. Tamer Coskun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 3 | |
| 4 | 2 | |
| 5 | Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA breakdown → | 232 |
| 6 | Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial breakdown → | 549 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.